Henry Bzdzuich and Richard Schiff v. United States Drug Enforcement Administration

76 F.3d 738, 1996 U.S. App. LEXIS 2622, 1996 WL 73903
CourtCourt of Appeals for the Sixth Circuit
DecidedFebruary 22, 1996
Docket94-4168
StatusPublished
Cited by10 cases

This text of 76 F.3d 738 (Henry Bzdzuich and Richard Schiff v. United States Drug Enforcement Administration) is published on Counsel Stack Legal Research, covering Court of Appeals for the Sixth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Henry Bzdzuich and Richard Schiff v. United States Drug Enforcement Administration, 76 F.3d 738, 1996 U.S. App. LEXIS 2622, 1996 WL 73903 (6th Cir. 1996).

Opinion

PER CURIAM.

Before this panel of the court is petitioners’ appeal from the United States Drug Enforcement Administration’s (DEA) denial of a request for an employment waiver for a pharmacist previously convicted of a controlled substance-related felony. For the reasons that follow, we affirm.

I. Background

Henry Bzdzuich (Bzdzuich) was licensed as a pharmacist in the State of Michigan in 1964. He worked at a pharmacy in Detroit owned by Jacob Schiff and his son Richard (Schiff) for 15 years. In 1982, he left Schiff to be the manager and 20 percent owner of a “Unarex” pharmacy. In 1987, pharmacists from 30 “Unarex” pharmacies were indicted for conspiracy to defraud insurance companies and divert controlled substances for profit. In 1988, Bzdzuich pled guilty to one count of racketeering activity (specifically, two instances of distribution of Preludin, a Schedule II controlled substance, outside the course of legitimate medical practice). Pursuant to this plea, he agreed to relinquish his pharmacy license. Bzdzuich received a four year prison sentence.

In 1993, the Michigan State Board of Pharmacy reinstated Bzdzuieh’s pharmacy license on the condition that he practice pharmacy under the personal supervision of a licensed pharmacist for 6 months, followed with one year of general supervision by a licensed pharmacist. Richard Schiff (Schiff), a licensed pharmacist for whom Bzdzuich had previously been employed, offered Bzdzuich employment. Pursuant to 21 C.F.R. § 1301.76(a), however, he could not employ Bzdzuich because of his controlled substance-related felonies.

On April 28, 1993, Schiff made an application for a waiver of the foregoing regulation. The DEA denied the application on October *741 25, 1993. Schiff filed for reconsideration on November 4, 1993, which was, again, denied on February 3, 1994. Before the foregoing denial, on January 17, 1994, Schiff sent in another application for a waiver. On October 11, 1994, the DEA sent a letter to Schiff denying the request for a waiver on the basis that insufficient time had elapsed since the conviction. Schiff and Bzdzuich filed this petition for review on November 10, 1994.

Petitioners raise three issues for our review: whether (1) the DEA’s denial of Schiff s application for an employment waiver was supported by substantial evidence; (2) the DEA deprived Bzdzuich of liberty or property without due process of law; and (3) the regulations relied on by the DEA in denying petitioners’ application for a waiver provided adequate warning of the standards to be used for such evaluations.

II. Conclusions of Law

Under 21 U.S.C. § 823(b), distributors of controlled substances must be registered by the Attorney General. The regulations for registration are contained in 21 C.F.R. Part 1301. These regulations provide that a registrant shall not employ any person who has been convicted of a felony relating to controlled substances. 21 C.F.R. § 1301.76(a). The DEA, however, has a practice of waiving this provision, but there are no regulations specifying the circumstances under which a waiver will be granted.

A. Substantial Evidence

Findings of fact by the DEA, if supported by substantial evidence, are conclusive. 21 U.S.C. § 877. Petitioners contend there was not substantial evidence to support the DEA’s denial of the waiver request. The October 11, 1994, denial letter states that, after consultation with DEA offices, “it is my decision to again deny your request for a waiver,” and mentions that Bzdzuich had been advised that he might consider having a waiver request submitted on his behalf in 18 to 24 months.

Petitioners maintain that the foregoing denial is not supported by substantial evidence because the DEA did not specify what evidence it was relying on in reaching its determination that insufficient time had elapsed since the conviction. Neither did the DEA explain why the period of time should be a factor in denying the application.

The DEA contends there is substantial evidence to support their decision. They contend that the October 1994 letter must be read in conjunction with the first denial letter of October 1993. The October 25, 1993, letter stated that the following factors were important in denying this request for a waiver:

(1) In December 1987, Mr. Bzdzuich pled guilty to one count of conspiracy to unlawfully distribute controlled substances and to one count of Racketeering Influenced and Corrupt Organizations; (2) Mr. Bzdzuich was involved in a large conspiracy with several associates from at least 1981 to 1985; (3) The case files indicate that individuals would bring Mr. Bzdzuich a stack of prescriptions approximately one inch thick and return the next day to pick up the controlled substances; (4) According to a telephone conversation between [Schiff] and Diversion Investigators of the Detroit DEA office, [Schiff] stated that Mr. Bzdzuich’s illegal activities were “quite extensive;” and (5) According to information you provided, Mr. Bzdzuich might be left in charge of the pharmacy in the event of vacations of store staff and that pharmacy technicians would “watch” Bzdzuich at other times.

The court is unaware of any precedents interpreting the phrase “substantial evidence” as used in 21 U.S.C. § 877. In other contexts, “[substantial evidence is more than a scintilla of evidence but less than a preponderance and is such relevant evidence as a reasonable mind might accept as adequate to support a conclusion.” Brainard v. Secretary of Health and Human Servs., 889 F.2d 679, 681 (6th Cir.1989). Applying this deferential standard to the DEA, its decision is supported by substantial evidence. Because the October 11, 1994, letter references the earlier denial, it is appropriate to look to the contents of the October 1993 letter to evaluate the evidence relied on by the DEA. That letter gives some reasonable *742 concerns, such as the extent of Bzdzuich’s involvement and insufficient supervision, that would support denial of a waiver. In addition, a reasonable person could believe that a waiting period would serve the prophylactic purpose of making petitioner aware of the serious responsibilities inherent in the privilege of being granted access to controlled substances.

B. Due Process

Petitioners contend they were deprived of their due process rights because they had no opportunity to be heard before the denial. In evaluating a due process claim the court must determine whether a property or liberty issue exists and, if so, what procedures are constitutionally required to protect that right.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Porter v. Probst
2014 Ohio 3789 (Ohio Court of Appeals, 2014)
Sevigny v USA
2014 DNH 157 (D. New Hampshire, 2014)
Walters v. UPMC Presbyterian Shadyside
31 Pa. D. & C.5th 281 (Alleghany County Court of Common Pleas, 2013)
Club Italia Soccer v. Shelby
Sixth Circuit, 2006
Bonds v. Tandy
457 F.3d 409 (Fifth Circuit, 2006)
Children's Healthcare is Legal Duty, Inc. v. Deters
92 F.3d 1412 (Sixth Circuit, 1996)
Patray v. Northwest Publishing, Inc.
931 F. Supp. 865 (S.D. Georgia, 1996)

Cite This Page — Counsel Stack

Bluebook (online)
76 F.3d 738, 1996 U.S. App. LEXIS 2622, 1996 WL 73903, Counsel Stack Legal Research, https://law.counselstack.com/opinion/henry-bzdzuich-and-richard-schiff-v-united-states-drug-enforcement-ca6-1996.